The Possible Importance of 3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia

被引:35
作者
Johansen, Silje [1 ]
Brenner, Annette K. [1 ,2 ]
Bartaula-Brevik, Sushma [2 ]
Reikvam, Hakon [1 ,2 ]
Bruserud, Oystein [1 ,2 ]
机构
[1] Haukeland Hosp, Dept Med, Sect Hematol, N-5021 Bergen, Norway
[2] Univ Bergen, Inst Clin Sci, Sect Hematol, N-5007 Bergen, Norway
关键词
acute myeloid leukemia; integrin; beta3; ACUTE MYELOGENOUS LEUKEMIA; FOCAL ADHESION KINASE; MESENCHYMAL STROMAL CELLS; TISSUE GROWTH-FACTOR; PROGNOSTIC-FACTOR; STEM-CELLS; GENE-EXPRESSION; LIGAND-BINDING; PROTEIN; AML;
D O I
10.3390/ijms19010251
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Acute myeloid leukemia (AML) is an aggressive bone marrow malignancy where the immature leukemia cells communicate with neighboring cells through constitutive cytokine release and through their cell surface adhesion molecules. The primary AML cells express various integrins. These heterodimeric molecules containing an and a chain are cell surface molecules that bind extracellular matrix molecules, cell surface molecules and soluble mediators. The 3 integrin (ITGB3) chain can form heterodimers only with the two chains IIb and V. These integrins are among the most promiscuous and bind to a large number of ligands, including extracellular matrix molecules, cell surface molecules and soluble mediators. Recent studies suggest that the two 3 integrins are important for leukemogenesis and chemosensitivity in human AML. Firstly, IIb and 3 are both important for adhesion of AML cells to vitronectin and fibronectin. Secondly, 3 is important for the development of murine AML and also for the homing and maintenance of the proliferation for xenografted primary human AML cells, and for maintaining a stem cell transcriptional program. These last effects seem to be mediated through Syk kinase. The 3 expression seems to be regulated by HomeboxA9 (HoxA9) and HoxA10, and the increased 3 expression then activates spleen tyrosine kinase (Syk) and thereby contributes to cytokine hypersensitivity and activation of 2 integrins. Finally, high integrin V/3 expression is associated with an adverse prognosis in AML and decreased sensitivity to the kinase inhibitor sorafenib; this integrin can also be essential for osteopontin-induced sorafenib resistance in AML. In the present article, we review the experimental and clinical evidence for a role of 3 integrins for leukemogenesis and chemosensitivity in AML.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming
    Kellaway, Sophie
    Chin, Paulynn S.
    Barneh, Farnaz
    Bonifer, Constanze
    Heidenreich, Olaf
    CELLS, 2020, 9 (12)
  • [42] Acute myeloid leukemia with DNMT3A mutations
    Li, Yunlong
    Zhu, Baosheng
    LEUKEMIA & LYMPHOMA, 2014, 55 (09) : 2002 - 2012
  • [43] FLT3 inhibitors in acute myeloid leukemia
    Wu, Mei
    Li, Chuntuan
    Zhu, Xiongpeng
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [44] Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia
    Kamga, Paul Takam
    Bassi, Giulio
    Cassaro, Adriana
    Midolo, Martina
    Di Trapani, Mariano
    Gatti, Alessandro
    Carusone, Roberta
    Resci, Federica
    Perbellini, Omar
    Gottardi, Michele
    Bonifacio, Massimiliano
    Kamdje, Armel Herve Nwabo
    Ambrosetti, Achille
    Krampera, Mauro
    ONCOTARGET, 2016, 7 (16): : 21713 - 21727
  • [45] An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape
    Bystrom, Rebecca
    Levis, Mark J.
    CURRENT ONCOLOGY REPORTS, 2023, 25 (04) : 369 - 378
  • [46] Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia
    Wang, Wenwen
    Bochtler, Tilmann
    Wuchter, Patrick
    Manta, Linda
    He, Haiju
    Eckstein, Volker
    Ho, Anthony D.
    Lutz, Christoph
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (05) : 392 - 398
  • [47] FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia The Start of an Era?
    Pemmaraju, Naveen
    Kantarjian, Hagop
    Ravandi, Farhad
    Cortes, Jorge
    CANCER, 2011, 117 (15) : 3293 - 3304
  • [48] Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia
    Bartaula-Brevik, Sushma
    Brattas, Marte Karen Lindstad
    Tvedt, Tor Henrik Anderson
    Reikvam, Hakon
    Bruserud, Oystein
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) : 377 - 387
  • [49] Hox gene dysregulation in acute myeloid leukemia
    De Braekeleer, Etienne
    Douet-Guilbert, Nathalie
    Basinko, Audrey
    Le Bris, Marie-Josee
    Morel, Frederic
    De Braekeleer, Marc
    FUTURE ONCOLOGY, 2014, 10 (03) : 475 - 495
  • [50] Current strategies in immunotherapy for acute myeloid leukemia
    Lichtenegger, Felix S.
    Schnorfeil, Frauke M.
    Hiddemann, Wolfgang
    Subklewe, Marion
    IMMUNOTHERAPY, 2013, 5 (01) : 63 - 78